Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
JCI Insight|September 8, 2022
Targeting BCL-XL in fibrolamellar hepatocellular carcinomaBassem Shebl, Denise Ng, Gadi Lalazar, et al.
Genome Biology|May 14, 2021
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathwaysWon Jin Ho, Rossin Erbe, Ludmila Danilova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic AdenocarcinomaParul Agarwal, Matthew Guo, Kabeer Munjal, et al.
Hepatology (Baltimore, Md.)|August 9, 2022
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironmentsDaniel J Zabransky, Ludmila Danilova, James M Leatherman, et al.
JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.
Nature Medicine|April 7, 2024
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trialMark Yarchoan, Edward J Gane, Thomas U Marron, et al.
Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Cancer Medicine|May 22, 2026
Outcomes of Hepatocellular Carcinoma involving the Portal Vein Main Trunk and/or the Inferior Vena Cava: Experience From a Multidisciplinary Liver Cancer ClinicI-Chia Liu, Atif Zaheer, Chen Hu, et al.
JCI Insight|May 18, 2021
Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinomaLing Li, Gilad Halpert, Michael G Lerner, et al.
Cancer Research Communications|August 14, 2024
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCCMari Nakazawa, Mike Fang, Tyrus Vong, et al.
Pageof 14